Humacyte, Inc. (NASDAQ:HUMAW) Short Interest Update

Humacyte, Inc. (NASDAQ:HUMAW) saw a significant drop in short interest in July. As of July 15th, there was short interest totaling 3,752 shares, a drop of 84.7% from the June 30th total of 24,488 shares. Based on an average daily trading volume, of 15,476 shares, the days-to-cover ratio is presently 0.2 days.

Humacyte Stock Performance

Shares of Humacyte stock traded up $0.00 during trading on Monday, reaching $0.01. The company’s stock had a trading volume of 707 shares, compared to its average volume of 17,233. The stock has a 50-day moving average price of $0.03 and a two-hundred day moving average price of $0.08. Humacyte has a one year low of $0.00 and a one year high of $0.58.

About Humacyte

Humacyte, Inc (NASDAQ:HUMAW) is a clinical-stage biotechnology company specializing in the development and manufacture of human acellular vessels (HAVs). These off-the-shelf, bioengineered vascular conduits are designed to serve as living implants for patients requiring vascular access, including those undergoing hemodialysis, as well as for peripheral artery disease and vascular trauma. Humacyte’s proprietary tissue-engineering platform leverages human vascular cells cultured on biodegradable scaffolds, which are subsequently decellularized to produce durable, non-immunogenic vessels that support natural tissue regeneration.

Founded in 2007 and headquartered in Durham, North Carolina, Humacyte has advanced its lead candidate, the HAV, through multiple clinical trials in the United States and Europe.